GSK 214094 (OSCAR)

A randomised, double-blind, placebo-controlled, study evaluating the efficacy and safety of otilimab IV in patients with severe pulmonary COVID-19 related disease.

Type: Interventional

Site and study lead:

• Oxford Road Campus: Dr Andrew Martin
• Wythenshawe Hospital – Dr Tim Felton

Patient group: COVID-19 patients on high flow oxygen, CPAP, BIPAP, NIV or intubated & ventilated